<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371133</url>
  </required_header>
  <id_info>
    <org_study_id>22/08/2019-05</org_study_id>
    <nct_id>NCT04371133</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Markers in Endometrioma</brief_title>
  <official_title>The Role of Serum Adropin, Salusin-α, Netrin-1, and Nesfatin-1 in Endometrioma and Their Association With Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Muğla Sıtkı Koçman University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Muğla Sıtkı Koçman University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators aimed to measure the serum levels of adropin, salusin-α, netrin-1, and
      nesfatin-1, anti-inflammatory effects of which have been demonstrated previously, in
      endometriosis patients and to find out any association of them with insulin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis is defined as the presence of endometrial gland and stroma outside the
      endometrial cavity affecting almost 10% of the women of reproductive age. Although benign, it
      disrupts the quality of life of the inflicted patients through symptoms such as dysmenorrhae,
      dyspareunia, chronic pelvic pain, and infertility. The pathogenesis of endometriosis has not
      yet been clearly elucidated, however, recent papers implies an underpinning role of
      inflammation There is a limited number of studies about the levels of these parameters in
      endometriosis and to date, no report is available on the levels of adropin and netrin-1 in
      endometriosis. Likewise, according to the investigator's literature search, no research
      explaining the association of endometriosis with insulin resistance has yet been published.
      In present study, in an attempt to describe inflammatory pathways playing a role in
      endometriosis pathogenesis, Investigators aimed to measure the levels of serum adropin,
      salusin-α, netrin-1, and nesfatin-1, anti-inflammatory effects of which have been priorly
      demonstrated, and to find out any association of them with insulin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Actual">March 15, 2020</completion_date>
  <primary_completion_date type="Actual">February 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Adropin level</measure>
    <time_frame>preoperative in the morning or Day 1 in outpatient clinic,preprandial for healthy volunteers</time_frame>
    <description>Serum Adropin level in ng/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Salusin-α</measure>
    <time_frame>preoperative in the morning or Day 1 in outpatient clinic, preprandial for healthy volunteers</time_frame>
    <description>Serum Salusin-α level in pg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Netrin-1</measure>
    <time_frame>preoperative in the morning or Day 1 in outpatient clinic, preprandial for healthy volunteers</time_frame>
    <description>Serum Netrin-1 level in pg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nesfatin-1</measure>
    <time_frame>preoperative in the morning or Day 1 in outpatient clinic, preprandial for healthy volunteers</time_frame>
    <description>Serum Nesfatin-1 level in ng/L</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Endometrioma</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Endometrioma</arm_group_label>
    <description>Endometrioma (n=23)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy controls Healthy volunteers n=25</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Adropin (ng/L)</intervention_name>
    <description>Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).</description>
    <arm_group_label>Endometrioma</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Salusin-α (pg/mL)</other_name>
    <other_name>Netrin-1 (pg/mL)</other_name>
    <other_name>Nesfatin-1 (ng/mL)</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum blood samples for each participant
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Laporoscopically and histopathologically diagnosed 23 endometrioma patients and 25 healthy
        individuals with no endometrioma constituting the control group were included to this
        study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ·Histopathologically confirmed diagnosis of endometrioma

        Exclusion Criteria:

          -  Any patients with DM,

          -  chronic kidney disease (CKD),

          -  CAD,

          -  heart failure (HF),

          -  cerebrovascular accident (CVA),

          -  malignancy,

          -  rheumatoid disorder,

          -  liver disease, and

          -  active infections were excluded from the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>patients with endometrioma</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burak Sezgin, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mugla Sıtkı Kocman University Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mugla Sıtkı Kocman University Faculty of Medicine</name>
      <address>
        <city>Muğla</city>
        <zip>48000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Muğla Sıtkı Koçman University</investigator_affiliation>
    <investigator_full_name>Burak Sezgin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>endometrioma</keyword>
  <keyword>adropin</keyword>
  <keyword>salusin-α</keyword>
  <keyword>netrin-1</keyword>
  <keyword>nesfatin-1</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

